![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
June 11, 2024
This phase 2 study is testing two variations of the triplet combination of azacitidine, venetoclax, and gilteritinib compared to standard therapy
June 13, 2024
This randomized phase 3 trial is comparing treatment with chemotherapy alone or with immunotherapy
April 11, 2024
This phase 2 imaging biomarker trial is evaluating whether novel biomarkers can accurately identify which patients will have better vs. worse survival outcomes early in their disease course
April 9, 2024
This phase 2/3 trial is comparing the safety and efficacy of treatment with nivolumab, ipilimumab, and sargramostim to treatment with nivolumab and ipilimumab alone
March 7, 2024
ACHIEVE is the first randomized phase 3 study to focus on older adults with advanced non-small cell lung cancer who are treated with pembrolizumab alone compared to those treated with pembrolizumab plus chemotherapy
March 7, 2024
This cancer care delivery study aims to provide out-of-pocket cost estimates and remote counseling to assist patients in navigating the financial aspects of cancer treatment
March 7, 2024
This phase 3 randomized controlled trial is comparing first-line treatment with osimertinib plus bevacizumab versus osimertinib alone in patients with metastatic, EGFR-mutant non-small cell lung cancer
February 9, 2024
This phase 2 trial is evaluating the combination of two different types of targeted drugs—sotorasib and panitumumab—that appear to be synergistic
February 9, 2024
Amidst a persistent drug shortage, the BRIDGE trial seeks another possible first-line treatment option for patients
December 19, 2023
This randomized phase 3 trial is testing whether second-line treatment with hepatic arterial infusion and systemic chemotherapy is more effective than systemic chemotherapy alone
December 19, 2023
This cancer care delivery study aims to improve medication adherence for patients with HR+/HER2- metastatic breast cancer
December 19, 2023
These four lung cancer treatment trials are all open and enrolling patients